Several studies (9-D) tzave evaluated the effects of various drugs on the number. magnitude and duration of episodes of-ST segment depress&in patients with angina pectoris. However, most of these studies provide only indirect evaluation of therapy for silent &hernia since they were primarily conducted for testing .he efficacy of antianginal drugs on angina frequency and ischemic threshold during exercise testing. Although some recent studies have specifically evaluated the role of beta-adrcncrgr blockers (13). Comnar? wren' disense was docummrcd by one or more of the pllwinp: coronary anery stenosis defined as a7lW luminal diameter narrowing of one or more major coronary arterie,: reversible perfusion defects on exercise thalliumZOt rcintigraphy; or presewe of Q waves diagnostic of myocardml mfarction on the 12 lead ECG. All patients had evidence of exercise-indilced ischemia before entry into the study. Pauents were excluded if they had conditions that precluded the use cf a beta-blocker or a calcium channel blocker. These included significant bronchospasm or emphysema. grea,er than first degree atrioventricular (AV) blwk conge*dve heart failure or sinus bradycardia 150 beatslmin Iwithwt medication). and those with past hypersensitivity to
Silent myocardiai ischemia own far more frequently than
do anginai symptoms in patients with known coronary artery disease (l-3). In patients with stable exertional antiina. silent ischemic events occur despite control of symptoms with conventional antianginal drugs (4). Because silent myocardial ischemia is not associated with any patient discomfort. treatment is generally not considered necessary. However. silent ischemia during daily life is associated wth an increased risk of coronary events and cardiac death tS_7). Antianginal therapy should possibly be directed toward control of lotal ischemic burden. i.e.. symptomatic and silent ischemia (8). Several studies (9-D) tzave evaluated the effects of various drugs on the number. magnitude and duration of episodes of-ST segment depress&in patients with angina pectoris. However, most of these studies provide only indirect evaluation of therapy for silent &hernia since they were primarily conducted for testing .he efficacy of antianginal drugs on angina frequency and ischemic threshold during exercise testing. Although some recent studies have specifically evaluated the role of beta-adrcncrgr blockers (13). Comnar? wren' disense was docummrcd by one or more of the pllwinp: coronary anery stenosis defined as a7lW luminal diameter narrowing of one or more major coronary arterie,: reversible perfusion defects on exercise thalliumZOt rcintigraphy; or presewe of Q waves diagnostic of myocardml mfarction on the 12 lead ECG. All patients had evidence of exercise-indilced ischemia before entry into the study. Pauents were excluded if they had conditions that precluded the use cf a beta-blocker or a calcium channel blocker. These included significant bronchospasm or emphysema. grea,er than first degree atrioventricular (AV) blwk conge*dve heart failure or sinus bradycardia 150 beatslmin Iwithwt medication). and those with past hypersensitivity to After the first active treatment phase all patients entered a second I week placebo period followed by crossnver 10 the alternate treatment for 3 mnre weeks. The dorcs of study medications were titrated in similar fashion as described (Fig. I) . Therapy with nitrates, calcium channel blockers and beta-adrenergic blockers was stopped for a minimum of 48 h or 5 half-lives of the prescribed drugs before enrollment in the study. but sublingual nitroglycerin was provided for relief of angina1 symptoms. T+ study protocol (Fig. I) consisted of a placebo run-in single blind study qualificatian phase lasting 7 to IO days, during which time matching placebo drugs were administered and patients were asked to keep angina diaries. Patients underwent ambulatory ECG monitoring for 48 h at the end of the placebo phase. Far study qualification all patients were required to have evidence of ambulatory ischemia during daily life with a minimum offive ischemic episodes or a total duration of ischemia a5 min/48 h. Patients who fulfilled these criteria were randomly assigned in a double blind manner tn receive atenolol. 50 mg once daily (9~03 AM). nr nifedipine. 20 mg three times daily (9:OO AM. 4:tHl PM and I I :W PML for I week, when 48 h ambulatory ECG monitaring was repealed. If ischemia during ambulatory KG monitoring was abolished. the treatment was continued at the same dosage for 2 mure weeks. However, if ambulatory ECG monitoring at the end of I week revealed the presence of transient ix-hernia, the doses of study medications were increased: alenolol to I00 mg once daily or nifedipine to 30'mg three times daily and continued for 2 mure weeks. Ambulatory ECG monitoring was rcpcatcd at the end of the 3 week treatment period ( An ischemic episode ~(1s defined as 21 nun horizontal or downsloping ST depression measured SO as from the 1 point and lasting rl min. The onset of the ixhemic episode was defined as the time when the ST segment became depressed E I mm and the offset time was defined after ST depression became 41 mm. An interval of at least 2 min during which the ST segment returned to the baseline was required before another episode was counted. The technician scanning the Holler tapes identified all potential ischemic episodes meeting these criteria and recorded the time of onset. peak ST depression and tertnination of ischemic events. Ekctrocardiographic tracings of these episodes were obtained at 25 mm/s speed for review. In addition, hourly examples of baseline ST segment without changes were recorded on paper. For each patient, the total number and duration of episodes were determined every 24 h. All episodes of ST segment depression were identified as symptomatic or silent on the basis of details obtained from the patient's diary.
Real-time printouts showing ST segment abnornmlities were blindly and independently reviewed by at least two experienced investigators. In case of a discrepancy between the two observers, the tapes were reanalyzed. Only those recordings with interpretable signals for 840 h during the 48 h monitoring period were included in the analysis.
Stalistkal anrdysis. Continuous measures were assessed using two-sample I test: analyses of categorical variables were conducted using Fisher's exact test. In the doubleblind phase. analysis al the patients on each trealmen~ kilenolol or nifedipine) who had abolition of irchemic events by the end of the respective active treatment period was accerplishcd using Fisher's exact test. The irchemic eventderived variables were evaluated using a repeated-measures crossover analysis of covariance. wi!h the baseline measure of interest serving as the covariate. after preli,.dnary test\ showed no evidence of stalislically sign/licant car&w etTecls from baseline to the end of the intervenina placebo washout period. Mean changes t=SEl within c& active treatment irom baseline to the end of the respective active treatment period were assessed using paired I tests. All statistical testing was performed at a two-sided signiiicana level of ao.05. (Table I) (Fig. 2) .
Study palienfs
The evaluation of study medications in abolishing Iran. sient ischemia during the monitoring period revealed atenolol to bc mnre effective than nifedipine. Treatment with atenolol was associated with a total suppression of ischemic activity in SW% of patients compared with only a 25% suppression rate with nifedipine (Fig. 3) .
EUeeLs of therapy on the manittg surge d ambulatory &ehemk activity (Fig. 4 to 6) . Because it is known that there is a surge in silent isehemic events between 6:tM AM and n~m. we evaluated the effects of study medications during this time period. During the placebo phase the hourly total number (Fig. 41 and duration (Fig. 5) (Fig. 3) . Advetw e&k.. Fewer adverse experiences were reported during atenolol therapy than were reported during treatment with nifedipine. During treatment with nifedipine dizziness was noted in five patients. peripheral edema in four. asthenia in four and paresthesia in two. In contrast. only twn patients rqwrted asthrraia during therapy with atenolol 
Discussion
hllwgcncsis of slknt iscbcmii in palknts with angina. Appropriate selection of a therapeutic regimen should be based on the underlying pathophysiologic process. Although the precise mechanism of silent myoeardial ischemia has not been established, on the basis of data showing minimal or no increase in heart rate during the 5 to I5 min preceding silent isehemic events. it has be& postulated that-silent i$ihemla during daily life occurs predominantly as a result of decrease in cwwwy blood supply ll7.18). This concept has been further supparted by findings that show that heart rate fis significantly lower at the onset of silent irchemic cvcntr during daily lie than during exercise testing in the same patients (Ii). However. findings from rcc&t studies in palierds with chronic exertional angina demonstrate that most episodes ofambulatory silent ischemia arc preceded by a sipiftcant increase in hean rate and blood pressure 119.20). Furthermore. silent ischemic events have been shown to increasc in frequency as well as duration during the morning hours when both heart rate and blood pressure have the greatest increases during the 24 h period (21).
There data, along with the results of recent reports (10-13) showing beneficial effects of beta-blocking agents in the trcantcnt of silent ischemic episodes. have clearly established a role of increased myocardial oxygen demand in the pathogenesis of ambulato~~rilent iaeh&ia. Neienhcless, some episodes of silent &hernia occur without any evidence for increased myoexdial oxygen demand and clearly must occur secondary to alterations it) coronary blocd supply 120).
Prcvtcms studits in therapy of silent isrhrmia. The antiischemic therapy for control of silent ixhemic events will vary depending on the clinical wbsets of patients being treated and the predominant mechanism rcspon$ihk for the ischemic episodes. All antianginal agents. includmg ottiates. adrenergic blockers (both alpha-and beta-blocking drugs1 and calcium channel blockers. arc eiTcctive in the management of patients with angina pectoris and have been shown to reduce the number and duration of ST segment deprcssien during ambulatory ECG monitoring 19-12). However. most of these studier were primarily dcstgncd to demonstrate the antianginal efficacy of these drugs and did not specifically evaluate the effects on ambulatory siknt ixhemia.
Several studies 113-U) have specifically evaluated the anti-ischemic effects of nitrates. beta-blockers and calcium channel blockers in patients with demonstrable silent myccardial Ischemin. Although the results of these studies show that all antianginal drugs arc effective in reducing the frcquency and duration of silent ischemie evcntr. carcfttl evaluation reveals considerable wiatian in their etXcaey. II has been suggested (13,15) that drugs that lower heart rate are more effective in controlling siknl iscbcmic cvcnt~ during dailv life. However. little information is available regarding direct comparison of anti-ischemic agents with different hemodynamic cifcets m the treatment of patients with amGent myocardial &hernia during routine daily activities.
Anti-kcbemk c6wcy of ate&d amd nifcdpinc dwizg ambulatory ECG monitoring. This study shows that both atenolol and nifcdipine arc elTcctive m reducing the fw quency and duration of silent ischemic events during daily life. Alenolol was signilicantlv lo < 0.051 more effective than mfedipine in red&g the &age &nbcr and average duration of silent ischemic events during the monitoring period. Alca more patients 00% vs. 25%) were free ai silent ixhcmia during therapy with atcnolol.
Although we cannot provide a specific reason for the difference in the anti-isehemic effieaey of alcnolol and nifedipine in this study. there arc several possible explanations. Beta-blockers exert their beneficial effects in patients with angma pecloris primarily by reducing the heat? rate, systolic blood prcrrw and cardiac contractility (22.23). Because all of our patients had evidence oiexertional myoeardial ischemia. it is likely that an increase in myoeardial oxygen demand played a significant role in the genesis ofambitlalory silent ischemia in these patients. Beeawe atctwlol produced a significant reduction in the heat rate response it is likely that this effect is partielly responsible for its greater antiischemic efficacy. Our results arc similar to those reported Treatment with nikdipine also produced a significant reduction in the number and duration of silent ischemic events: bowever. its anti-ischemic effects were less rcmarkable than :hose of atenolol. Although nifedipine was associated with 8 smaller degree of reduction in blood presrure. it failed to lower the heart rate response, which may panly account for its lesser anti-ischemic efficacy in our patients.
Role d stmald In reducing dknt Bohemia during Ihr early maning hours. The a~cnolol was rigniticanlly more effective tp < 0.05) thw nifedipine in suppressing the ischemic activity during the morning hours hetwvwn 6~00 aa and noon IFig. 61. This bugge\ts significant residual anti-ixhemic et&cl of atenolol 24 h after dosing and is consistent with previous data 04) showing sustained heta.blocking efficacy of atcnolol during a Gmilar dosing schedule. Because nifcdipine has a relatively shorter halfWe I6 lo tl h) and was given nt I I:00 PM and 993 AM. it is possible that a therapeutic gap existed between 6~00 AM and lO:OO AM (Fig. 4 and 5) .
Although this hypothesis is not established. the morning surge in transient ischemic events may act as a trigger for acute myocardial infarction and sudden cardiac death, which occur with increased frequency during this time period. The anti-ischemic effects of atenolol in suppressing the morning surge of ischemic activity may prove beneficial in reducing the risk of myocardial infarction and sudden cardiac death (251.
Conelusions. Atenolol and nifedipine are e&ctive antiischemic drugs in the treatment of ambulatory silent isch emia. In most patients. atenolol effectively reduced the morning surge of irchcmic activity and abolished silent ischemia between 6:OO AM and nwn. Treatment with atenolol may reduce the risk of acute myocardial infarction and sudden cardiac death by suppressing silent ischemic events. particularly during the morning hours when the risk of these events is significantly increased. Large controlled studier are needed. however. to document the knelicial efkcts of anti-ischemic therapy in patients with ambulatory silent ischemia.
